The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib (Q40328353)
scientific article published on May 2006
Language:
(P31) (Q13442814)
(P50) (Q37828910)
(Q39048942)
(Q116998253)
(Q104516503)
(Q116998267)
(Q88083722)
(Q19358146)
(P304) 420-427
(P433) 2
(P478) 207
(P577) Monday, May 1, 2006
(P1433) (Q1524270)
(P1476) "The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib" (language: en)
(P2093) Maria Napolitano
Giuseppe Viglietto
(P2860) (Q36028642)
other details
description scientific article published on May 2006

External Links